|Gene Name||matrix metallopeptidase 14 (membrane-inserted)|
|Synonym(s)||matrix metalloproteinase 14 (membrane-inserted), type 1 matrix metalloprotease 14, Membrane type 1-MMP, MT1-MMP, MT-MMP-1, AI325305|
|Institutional Source||Beutler Lab|
|Chromosomal Location||54,431,604-54,441,258 bp (+)|
|Type of Mutation||missense|
|DNA Base Change
|T to C at 54,439,999 bp (GRCm38)|
|Amino Acid Change||Serine changed to Proline|
|Gene Model||not available|
|Predicted Effect||possibly damaging
PolyPhen 2 Score 0.777 (Sensitivity: 0.85; Specificity: 0.93)
|Phenotypic Category||craniofacial, growth/size, lethality-embryonic/perinatal, life span-post-weaning/aging, reproductive system, vision/eye|
|Alleles Listed at MGI|
|Mode of Inheritance||Autosomal Recessive|
|Local Stock||Sperm, gDNA|
|Last Updated||12/12/2013 6:56 PM by Stephen Lyon|
The cartoon mutation was recovered serendipitously in the course of confirming an immunological phenodeviant. Cartoon mice show craniofacial anomalies: a shortened head and snout, and very large-appearing eyes (Figure 1). The physical development of cartoon mice is retarded or arrested at an early stage. The average body weight of 7-week-old cartoon mice is 7.75±0.62g, compared to 20.56±2.38g for their wild type littermates.
The average life span of cartoon mice is approximately 3 months, and homozygotes do not breed. In heterozygote crosses, only half of the expected number of homozygotes are born, consistent with some degree of embryonic lethality.
|Nature of Mutation|
The cartoon mutation mapped to Chromosome 14, and corresponds to a T to C transition at position 1642 of the Mmp14 transcript, in exon 9 of 10 total exons.
The mutated nucleotide is indicated in red lettering, and causes a serine to proline substitution at residue 466 of the Mmp14 protein.
MMP14 (matrix metallopeptidase 14; also MT1-MMP, membrane type 1- matrix metalloproteinase) is a 582 amino acid membrane-type metalloproteinase, one of six members of this subclass of metalloproteinases [reviewed in (1)]. Like other metalloproteinases (Figure 2A), at its N terminus MMP14 contains a signal peptide with a hydrophobic core (amino acids 1-20) followed by a propeptide domain (Figure 2B) (2;3). The propeptide domain, and specifically four amino acids (YGYL) within it, functions as an “intramolecular chaperone” for MMP14; i.e. deletion of the entire propeptide or mutation of these four amino acids results in a membrane-bound but nonfunctional protein, and expression of the propeptide in trans restores proteolytic activity (4;5). The bulk of the protein then consists of the core enzyme catalytic domain containing a Zn2+-binding site. A hinge region follows, and a hemopexin-like domain that contains several hemopexin-like repeats (2;3).
Three conserved insertion sequences (IS-1, IS-2 and IS-3) distinguish the membrane-type MMPs from MMPs, which are secreted proteins. IS-1 is an eleven amino acid insertion containing a proprotein convertase cleavage sequence recognized by furin-like proteins, and located between the propeptide domain and the catalytic domain of MMP14 (2;3). Cleavage of this sequence activates MMP14 (6). IS-2 is an eight amino acid insertion in the catalytic domain which may influence proteolytic function toward the substrate proMMP2 (3). Near the C-terminus and within the hemopexin domain of MMP14, IS-3 is an approximately 60 amino acid insertion containing a stretch of 24 hydrophobic amino acids that form a transmembrane domain, as well as a short cytoplasmic tail (2;3). IS-3 is required for proper localization to the cell membrane (7;8). The cytoplasmic tail is predicted to serve a cell signaling role, and contains three putative phosphorylation sites (S577, Y573, T567) with unknown function (9).
The cartoon mutation results in substitution of a proline for serine 466, which lies near the center of the hemopexin-like domain.
The crystal structure of a recombinant MMP14 catalytic domain (Figure 3) in a 1:1 complex with bovine tissue inhibitor of metalloproteinases-2 (TIMP-2) has been solved [Figure 4 (PDB:1BQQ); (10)]. MMP14 and TIMP-2 interact through six sequentially separated segments. TIMPs not only inhibit MMPs, they are also known to exhibit growth factor-like activity and inhibit angiogenesis (reviewed in (11;12)). TIMP-2 in complex with MMP14 assists in the processing of progelatinase A (13-15), a process necessary for remodeling processes and degenerative diseases as well as tumor invasion and metastasis (reviewed in (10)). The catalytic domain of MMP14 is a spherical molecule that contains an active-site cleft. The body of the molecule is a five-stranded mixed β-pleated sheet with three surface loops on the convex side and two α-helices on the concave side. The active site of MMP14 contains four metal sites that bind two zinc and two calcium ions, similar to other MMPs. MMP14 has a uniqe conformation and length of the N-terminal segment, a MT-loop, and the sV-hB loop similar to other solved MMP-TIMP structures (16). In addition, the substrate binding region of MMP14 looks similar to other MMPs (10).
Crystallization of full-length porcine MMP1, a "typical" MMP, shows a catalytic domain, hemopexin-like domain, and hinge domain similar to those found in MMP14 [Figure 5 (PDB:1FBL); (17)]. Similar to MMP14, a linker connects the tightly packed N-terminal catalytic domain and the C-terminal hemopexin-like domains. Examination of the C-terminal hemopexin-like-containing structure revealed that each of the hemopexin-like domains contains a sheet of four antiparallel β-strands to form a four-bladed propeller structure. Alignment of the catalytic domains of porcine MMP1 with human MMP14 reveals the structural similarities between typical and membrane-bound MMPs (Figure 6).
Northern blot analysis detected Mmp14 transcript in most tissues examined, including heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas (3). Several cancer cell lines (squamous cell carcinoma OSC-19, bladder carcinoma T24, osteosarcoma SK-ES-1) also express Mmp14 transcript (3). MMP14 is localized at the cell membrane (2;3).
The extracellular matrix (ECM) is a dense three-dimensional mesh of proteins (e.g. collagen, fibronectin) and proteoglycans (e.g. heparan sulfate, chondroitin sulfate proteoglycans) secreted by cells, and surrounding and supporting the cells of the body. ECM serves both structural and signaling roles, providing anchorage for cells, regulating cell migration and sequestering/releasing growth factors and cytokines. Cells express receptors for distinct components of the ECM, and receptor engagement activates multiple signaling pathways regulating development, morphogenesis and homeostasis. The MMPs are zinc endopeptidases capable of degrading structural components of the ECM, and contribute to these processes by modifying the cell-ECM interface and releasing sequestered molecules (18). Conversely, cancer cells can activate MMPs in order to break down basement membranes during metastasis.
Tumor tissues express a variety of MMPs with several functions (Figure 7); MMP inhibitors have received much attention as potential cancer therapeutics (19). MMP14 was first identified as a proteinase and activator of proMMP2 (2;13), a significant finding due to the association of MMP2 (also gelatinase A) with tumor invasion. MMP2 can degrade type IV collagen, a major component of the basement membrane, and is found in activated form in carcinomas with lymph node or distant metastasis (20;21). In addition, MMP2-deficient mice have significantly reduced tumor invasion, metastasis and angiogenesis in tumor models (22). Transgenic overexpression of MMP14 in mouse mammary glands results in increased MMP2 activation, lymphocytic infiltration, fibrosis, hyperplasia, dysplasia and adenocarcinoma (23). Recently, MMP14 has been shown to directly promote tumor cell growth in a three dimensional matrix by proteolysis of type I collagen (24). Thus, MMP14 is thought promote tumor invasion by both activating MMP2 in tumors and degrading the physical ECM barrier to tumor cell penetration.
MMPs may help tumor cells escape from immune surveillance (19). Some MMPs cleave receptors and chemokines that promote the development, proliferation or chemotaxis of tumor-fighting T lymphocytes, natural killer cells, neutrophils and macrophages. For example, MMP9 can cleave and inactivate interleukin-2 receptor-α (IL-2Rα), a positive regulator of T cell development and proliferation (25). Cervical cancer cells can induce release of IL-2Rα on encountered T cells via MMP9 in vitro (25). A similar role for MMP14 is unconfirmed, but MMP14 is positioned ideally to function in this manner. However, in a situation contrary to this hypothesis, MMP14 can cleave CXCL12 (also stromal-cell-derived factor 1, SDF1), a ligand for CXCR4 (26). Inhibition of CXCL12 binding to CXCR4 has been shown to reduce breast cancer cell metastasis to lung and lymph nodes (27). Thus, cleavage of CXCL12 may prevent its association with CXCR4 and inhibit metastasis.
In addition to MMP2, substrates for MMP14 include a wide variety of ECM proteins such as fibronectin, proteoglycans, laminin, and collagens (6;28;29). This broad substrate specificity suggests that MMP14 may contribute to numerous biological events that rely on structural remodeling of the ECM, particularly during development. Targeted deletion of MMP14 confirmed that MMP14 functions in very many developmental processes (30). MMP14-deficient mice develop a severe skeletal and soft connective tissue phenotype characterized by craniofacial dysmorphism, arthritis, osteopenia and fibrosis of soft tissues (30). Interestingly, although MMP14-/- mice appear normal at birth, growth impairment becomes evident by 5 days of age and continues throughout life, with animals dying between days 50 and 90 (30). Thus, collagen remodeling only relies on MMP14 postnatally, and an MMP14-independent mechanism holds this function during prenatal development.
All of the MMP14-/- mouse phenotypes recognized to date are caused by a generalized deficiency of cellular collagenolytic activity (30). MMP14-/- skin or bone marrow-derived fibroblasts are unable to degrade type I collagen fibrils in vitro (30). As a result, mutant mice develop severe and progressive fibrosis in many tissues. Bone formation and growth are severely impaired in MMP14-/- mice, for example in the skull and long bones, and may also be attributed to defective collagen degradation, because proper bone growth requires the coordinated remodeling of bone and adjacent soft connective tissues. MMP14-/- osteogenic progenitor cells cannot degrade a type I collagen matrix. Likely as a compensatory mechanism for loss of the ability to remodel connective tissue, bone remodeling appears to be accelerated in MMP14-deficient mice. Excessive bone resorption occurs in MMP14-/- mice, particularly at bone/soft tissue interfaces (30). This defect is compounded by the progressive entrapment of osteogenic cells in the ECM of the periosteum, preventing them from reaching the bone surface where bone matrix deposition occurs (30). Together, these effects cause a net bone resorption, contributing (along with defective formation of secondary ossification centers) to dwarfed stature, cranial dysmorphism, and progressive osteopenia (30;31).
A recent study found that MMP14 forms a complex with fibroblast growth factor receptor 2 (FGFR2) and ADAM9 in osteoblasts (Figure 8) (32). FGFRs are essential for ossification during skull development (33). Furthermore, mutations that activate FGFR1 and FGFR2 result in several human craniofacial diseases (e.g. Crouzon syndrome (OMIM: #123500) and Apert syndrome (OMIM: #101200)) (34). This study found that the formation of the FGF2-MMP14-ADAM9 complex protects FGFR2 from ADAM9-mediated ectodomain shedding on the cell surface (32). Analysis of Mmp14-/- osteoblasts found that FGF-induced proliferation was compromised with a concomitant upregulation in ADAM9 and FGFR2 shedding (32). Interestingly, depletion of Adam9 can rescue FGFR2 signaling and restore skull bone growth in Mmp14-/- embryos.
In most other MMP mouse mutants, embryonic and postnatal development occurs normally. In contrast, the severe phenotype observed in MMP14-deficient mice supports the conclusion that MMP14 is the major postnatal type I collagenolytic activity. Whether MMP14 activity towards other ECM substrates also contributes to development is unknown. MMP2 is thought to be an important substrate for MMP14 in cancer progression. However, MMP2-null mice have no developmental defects other than being slightly smaller than wild type mice, suggesting that MMP2 is not a predominant substrate for MMP14 during development (35).
Cartoon mice harbor a mutation in the center of the hemopexin-like domain. Using recombinant proteins and cultured cell lines, the hemopexin-like domain has been shown to mediate a variety of functions and protein interactions. It has been shown to be required for MMP14 processing to its mature, active form, and trafficking to the cell membrane (36). Domain swapping experiments demonstrated that the MMP14 hemopexin-like domain is required, independently of the catalytic domain, for cell migration (37). MMP14-induced cell migration activates the small Rho GTPase family member Rac, and dominant negative Rac blocks MMP14-induced migration (37). Thus, it is possible that mutation of the hemopexin-like domain completely inhibits MMP14 function (similar to a null mutation) by blocking its maturation and trafficking, and/or that cell migration is specifically impaired.
The hemopexin-like domain mediates MMP14 homodimer formation, postulated to promote localized concentrations of MMP14 to facilitate MMP2 activation (38). Since MMP2 is unlikely to be a developmentally important MMP14 substrate, homodimerization may serve some other function. The MMP14 hemopexin-like domain also mediates association with and cleavage of the hyaluronan receptor CD44 (39), which contributes to lymphocyte activation as well as metastatic potential in cancer cells.
In light of the recent findings by Chan et al. (32) as discussed in the "Background" section, it is probable that the craniofacial abnormalities observed in the cartoon mice are a result in defective FGFR2-mediated signaling following upregulated ADAM9 activity (Figure 9).
Cartoon genotyping is performed by amplifying the region containing the mutation using PCR, followed by sequencing of the amplified region to detect the single nucleotide transition. The same primers are used for PCR amplification and for sequencing.
Car(F): 5’- ACGCCCAGTATCCAACCACTCC -3’
Car(R): 5’- TGGAAAGACTGAGGGTACTACACATG -3’
1) 94°C 2:00
2) 94°C 0:15
3) 58°C 0:20
4) 72°C 1:00
5) repeat steps (2-4) 35X
6) 72°C 5:00
7) 4°C ∞
The following sequence of 320 nucleotides (from Genbank genomic region NC_000080 for linear genomic sequence of Mmp14) is amplified:
8244 acgccca gtatccaacc actccccttt ccttcccctc
8281 ccccaggtac taccggttca atgaagaatt cagggcagtg gacagcgagt accctaaaaa
8341 catcaaagtc tgggaaggaa tccctgaatc tcccaggggg tcattcatgg gcagtgatga
8401 aggtgagtga agcaaaggaa actatagaga agggcaagct tggggagcca aggaaaagca
8461 gaaaggcagg tcttgtggaa agcattgatg gtgtagcagt gggggctggg ggcttgccag
8521 gaaagagcca agtgttttca tgtgtagtac cctcagtctt tcca
Primer binding sites are underlined; the mutated T is highlighted in red.
1. Fillmore, H. L., VanMeter, T. E., and Broaddus, W. C. (2001) Membrane-Type Matrix Metalloproteinases (MT-MMPs): Expression and Function during Glioma Invasion. J. Neurooncol.. 53, 187-202.
2. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994) A Matrix Metalloproteinase Expressed on the Surface of Invasive Tumour Cells. Nature. 370, 61-65.
3. Takino, T., Sato, H., Yamamoto, E., and Seiki, M. (1995) Cloning of a Human Gene Potentially Encoding a Novel Matrix Metalloproteinase having a C-Terminal Transmembrane Domain. Gene. 155, 293-298.
4. Cao, J., Hymowitz, M., Conner, C., Bahou, W. F., and Zucker, S. (2000) The Propeptide Domain of Membrane Type 1-Matrix Metalloproteinase Acts as an Intramolecular Chaperone when Expressed in Trans with the Mature Sequence in COS-1 Cells. J. Biol. Chem.. 275, 29648-29653.
5. Pavlaki, M., Cao, J., Hymowitz, M., Chen, W. T., Bahou, W., and Zucker, S. (2002) A Conserved Sequence within the Propeptide Domain of Membrane Type 1 Matrix Metalloproteinase is Critical for Function as an Intramolecular Chaperone. J. Biol. Chem.. 277, 2740-2749.
6. Pei, D., and Weiss, S. J. (1996) Transmembrane-Deletion Mutants of the Membrane-Type Matrix Metalloproteinase-1 Process Progelatinase A and Express Intrinsic Matrix-Degrading Activity. J. Biol. Chem.. 271, 9135-9140.
7. Nakahara, H., Howard, L., Thompson, E. W., Sato, H., Seiki, M., Yeh, Y., and Chen, W. T. (1997) Transmembrane/cytoplasmic Domain-Mediated Membrane Type 1-Matrix Metalloprotease Docking to Invadopodia is Required for Cell Invasion. Proc. Natl. Acad. Sci. U. S. A.. 94, 7959-7964.
8. Urena, J. M., Merlos-Suarez, A., Baselga, J., and Arribas, J. (1999) The Cytoplasmic Carboxy-Terminal Amino Acid Determines the Subcellular Localization of proTGF-(Alpha) and Membrane Type Matrix Metalloprotease (MT1-MMP). J. Cell. Sci.. 112 ( Pt 6), 773-784.
9. Lehti, K., Valtanen, H., Wickstrom, S. A., Lohi, J., and Keski-Oja, J. (2000) Regulation of Membrane-Type-1 Matrix Metalloproteinase Activity by its Cytoplasmic Domain. J. Biol. Chem.. 275, 15006-15013.
10. Fernandez-Catalan, C., Bode, W., Huber, R., Turk, D., Calvete, J. J., Lichte, A., Tschesche, H., and Maskos, K. (1998) Crystal Structure of the Complex Formed by the Membrane Type 1-Matrix Metalloproteinase with the Tissue Inhibitor of Metalloproteinases-2, the Soluble Progelatinase A Receptor. EMBO J.. 17, 5238-5248.
11. Cawston, T. (1998) Matrix Metalloproteinases and TIMPs: Properties and Implications for the Rheumatic Diseases. Mol. Med. Today. 4, 130-137.
12. Gomez, D. E., Alonso, D. F., Yoshiji, H., and Thorgeirsson, U. P. (1997) Tissue Inhibitors of Metalloproteinases: Structure, Regulation and Biological Functions. Eur. J. Cell Biol.. 74, 111-122.
13. Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., and Goldberg, G. I. (1995) Mechanism of Cell Surface Activation of 72-kDa Type IV Collagenase. Isolation of the Activated Form of the Membrane Metalloprotease. J. Biol. Chem.. 270, 5331-5338.
14. Strongin, A. Y., Marmer, B. L., Grant, G. A., and Goldberg, G. I. (1993) Plasma Membrane-Dependent Activation of the 72-kDa Type IV Collagenase is Prevented by Complex Formation with TIMP-2. J. Biol. Chem.. 268, 14033-14039.
15. Will, H., Atkinson, S. J., Butler, G. S., Smith, B., and Murphy, G. (1996) The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation. Regulation by TIMP-2 and TIMP-3. J. Biol. Chem.. 271, 17119-17123.
16. Gomis-Ruth, F. X., Maskos, K., Betz, M., Bergner, A., Huber, R., Suzuki, K., Yoshida, N., Nagase, H., Brew, K., Bourenkov, G. P., Bartunik, H., and Bode, W. (1997) Mechanism of Inhibition of the Human Matrix Metalloproteinase Stromelysin-1 by TIMP-1. Nature. 389, 77-81.
17. Li, J., Brick, P., O'Hare, M. C., Skarzynski, T., Lloyd, L. F., Curry, V. A., Clark, I. M., Bigg, H. F., Hazleman, B. L., and Cawston, T. E. (1995) Structure of Full-Length Porcine Synovial Collagenase Reveals a C-Terminal Domain Containing a Calcium-Linked, Four-Bladed Beta-Propeller. Structure. 3, 541-549.
18. Mott, J. D., and Werb, Z. (2004) Regulation of Matrix Biology by Matrix Metalloproteinases. Curr. Opin. Cell Biol.. 16, 558-564.
19. Egeblad, M., and Werb, Z. (2002) New Functions for the Matrix Metalloproteinases in Cancer Progression. Nat. Rev. Cancer.. 2, 161-174.
20. Tokuraku, M., Sato, H., Murakami, S., Okada, Y., Watanabe, Y., and Seiki, M. (1995) Activation of the Precursor of Gelatinase A/72 kDa Type IV collagenase/MMP-2 in Lung Carcinomas Correlates with the Expression of Membrane-Type Matrix Metalloproteinase (MT-MMP) and with Lymph Node Metastasis. Int. J. Cancer. 64, 355-359.
21. Ueno, H., Nakamura, H., Inoue, M., Imai, K., Noguchi, M., Sato, H., Seiki, M., and Okada, Y. (1997) Expression and Tissue Localization of Membrane-Types 1, 2, and 3 Matrix Metalloproteinases in Human Invasive Breast Carcinomas. Cancer Res.. 57, 2055-2060.
22. Itoh, T., Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H., and Itohara, S. (1998) Reduced Angiogenesis and Tumor Progression in Gelatinase A-Deficient Mice. Cancer Res.. 58, 1048-1051.
23. Ha, H. Y., Moon, H. B., Nam, M. S., Lee, J. W., Ryoo, Z. Y., Lee, T. H., Lee, K. K., So, B. J., Sato, H., Seiki, M., and Yu, D. Y. (2001) Overexpression of Membrane-Type Matrix Metalloproteinase-1 Gene Induces Mammary Gland Abnormalities and Adenocarcinoma in Transgenic Mice. Cancer Res.. 61, 984-990.
24. Hotary, K. B., Allen, E. D., Brooks, P. C., Datta, N. S., Long, M. W., and Weiss, S. J. (2003) Membrane Type I Matrix Metalloproteinase Usurps Tumor Growth Control Imposed by the Three-Dimensional Extracellular Matrix. Cell. 114, 33-45.
25. Sheu, B. C., Hsu, S. M., Ho, H. N., Lien, H. C., Huang, S. C., and Lin, R. H. (2001) A Novel Role of Metalloproteinase in Cancer-Mediated Immunosuppression. Cancer Res.. 61, 237-242.
26. McQuibban, G. A., Butler, G. S., Gong, J. H., Bendall, L., Power, C., Clark-Lewis, I., and Overall, C. M. (2001) Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-Derived Factor-1. J. Biol. Chem.. 276, 43503-43508.
27. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., Barrera, J. L., Mohar, A., Verastegui, E., and Zlotnik, A. (2001) Involvement of Chemokine Receptors in Breast Cancer Metastasis. Nature. 410, 50-56.
28. Ohuchi, E., Imai, K., Fujii, Y., Sato, H., Seiki, M., and Okada, Y. (1997) Membrane Type 1 Matrix Metalloproteinase Digests Interstitial Collagens and Other Extracellular Matrix Macromolecules. J. Biol. Chem.. 272, 2446-2451.
29. d'Ortho, M. P., Will, H., Atkinson, S., Butler, G., Messent, A., Gavrilovic, J., Smith, B., Timpl, R., Zardi, L., and Murphy, G. (1997) Membrane-Type Matrix Metalloproteinases 1 and 2 Exhibit Broad-Spectrum Proteolytic Capacities Comparable to Many Matrix Metalloproteinases. Eur. J. Biochem.. 250, 751-757.
30. Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S. A., Mankani, M., Robey, P. G., Poole, A. R., Pidoux, I., Ward, J. M., and Birkedal-Hansen, H. (1999) MT1-MMP-Deficient Mice Develop Dwarfism, Osteopenia, Arthritis, and Connective Tissue Disease due to Inadequate Collagen Turnover. Cell. 99, 81-92.
31. Zhou, Z., Apte, S. S., Soininen, R., Cao, R., Baaklini, G. Y., Rauser, R. W., Wang, J., Cao, Y., and Tryggvason, K. (2000) Impaired Endochondral Ossification and Angiogenesis in Mice Deficient in Membrane-Type Matrix Metalloproteinase I. Proc. Natl. Acad. Sci. U. S. A.. 97, 4052-4057.
32. Chan, K. M., Wong, H. L., Jin, G., Liu, B., Cao, R., Cao, Y., Lehti, K., Tryggvason, K., and Zhou, Z. (2012) MT1-MMP Inactivates ADAM9 to Regulate FGFR2 Signaling and Calvarial Osteogenesis. Dev. Cell.. .
33. Ornitz, D. M., and Marie, P. J. (2002) FGF Signaling Pathways in Endochondral and Intramembranous Bone Development and Human Genetic Disease. Genes Dev.. 16, 1446-1465.
34. Miraoui, H., and Marie, P. J. (2010) Fibroblast Growth Factor Receptor Signaling Crosstalk in Skeletogenesis. Sci. Signal.. 3, re9.
35. Itoh, T., Ikeda, T., Gomi, H., Nakao, S., Suzuki, T., and Itohara, S. (1997) Unaltered Secretion of Beta-Amyloid Precursor Protein in Gelatinase A (Matrix Metalloproteinase 2)-Deficient Mice. J. Biol. Chem.. 272, 22389-22392.
36. Atkinson, S. J., Roghi, C., and Murphy, G. (2006) MT1-MMP Hemopexin Domain Exchange with MT4-MMP Blocks Enzyme Maturation and Trafficking to the Plasma Membrane in MCF7 Cells. Biochem. J.. 398, 15-22.
37. Cao, J., Kozarekar, P., Pavlaki, M., Chiarelli, C., Bahou, W. F., and Zucker, S. (2004) Distinct Roles for the Catalytic and Hemopexin Domains of Membrane Type 1-Matrix Metalloproteinase in Substrate Degradation and Cell Migration. J. Biol. Chem.. 279, 14129-14139.
38. Itoh, Y., Takamura, A., Ito, N., Maru, Y., Sato, H., Suenaga, N., Aoki, T., and Seiki, M. (2001) Homophilic Complex Formation of MT1-MMP Facilitates proMMP-2 Activation on the Cell Surface and Promotes Tumor Cell Invasion. EMBO J.. 20, 4782-4793.
|Science Writers||Eva Marie Y. Moresco, Anne Murray|
|Authors||Xin Du, Bruce Beutler|